Effect of levetiracetam on epilepsy-related quality of life

Joyce A. Cramer, Celestina Arrigo, Geneviève Van Hammée, Laura J. Gauer, James Cereghino

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Purpose: To evaluate the short-term effect of levetiracetam (LEV; UCB L059) as add-on therapy on health-related quality of life in the treatment of refractory partial-onset seizures. Methods: Patients were enrolled in protocol UCB N132 if they had ≥ 12 partial-onset seizures with or without secondary generalization during the 12-week baseline period with a minimum of two seizures every 4 weeks. Randomization was made to placebo, LEV 1,000 mg, or LEV 3,000 mg, with sample size based on seizure frequency reduction. The 31-item Quality of Life in Epilepsy (QOLIE-31) questionnaire was completed by 246 patients at the end of baseline and at 18-week follow-up, or earlier if withdrawn. Results: Significant differences were found among the three treatment groups for Seizure Worry (p = 0.0003), Overall Quality of Life (p = 0.04), and Cognitive Functioning domains (p = 0.01), as well as the Total Score (p = 0.009). Responders (≥50% partial onset seizure reduction) had significant improvements in all areas, except Medication Effect, compared with nonresponders (all p > 0.006). Clinically noticeable improvement (≥10% change from baseline to follow-up) was perceived by LEV 3,000 mg responders in all areas, except Emotional Well-Being, by LEV 1,000 mg responders in 5 of 9 areas, and by placebo responders in 2 of 9 areas. Conclusions: Addition of LEV to standard medication seems to have a positive impact on health-related quality of life, particularly among responders in this short-term study. These exploratory analyses require additional studies to evaluate long-term changes in a larger population.

Original languageEnglish (US)
Pages (from-to)868-874
Number of pages7
JournalEpilepsia
Volume41
Issue number7
StatePublished - 2000

Fingerprint

etiracetam
Epilepsy
Seizures
Quality of Life
Placebos
Random Allocation
Sample Size
Therapeutics

Keywords

  • Clinical trial
  • Levetiracetam
  • QOLIE-31
  • Quality of life
  • Seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cramer, J. A., Arrigo, C., Van Hammée, G., Gauer, L. J., & Cereghino, J. (2000). Effect of levetiracetam on epilepsy-related quality of life. Epilepsia, 41(7), 868-874.

Effect of levetiracetam on epilepsy-related quality of life. / Cramer, Joyce A.; Arrigo, Celestina; Van Hammée, Geneviève; Gauer, Laura J.; Cereghino, James.

In: Epilepsia, Vol. 41, No. 7, 2000, p. 868-874.

Research output: Contribution to journalArticle

Cramer, JA, Arrigo, C, Van Hammée, G, Gauer, LJ & Cereghino, J 2000, 'Effect of levetiracetam on epilepsy-related quality of life', Epilepsia, vol. 41, no. 7, pp. 868-874.
Cramer JA, Arrigo C, Van Hammée G, Gauer LJ, Cereghino J. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia. 2000;41(7):868-874.
Cramer, Joyce A. ; Arrigo, Celestina ; Van Hammée, Geneviève ; Gauer, Laura J. ; Cereghino, James. / Effect of levetiracetam on epilepsy-related quality of life. In: Epilepsia. 2000 ; Vol. 41, No. 7. pp. 868-874.
@article{cd8b4df3bd834b748542ba2243d75876,
title = "Effect of levetiracetam on epilepsy-related quality of life",
abstract = "Purpose: To evaluate the short-term effect of levetiracetam (LEV; UCB L059) as add-on therapy on health-related quality of life in the treatment of refractory partial-onset seizures. Methods: Patients were enrolled in protocol UCB N132 if they had ≥ 12 partial-onset seizures with or without secondary generalization during the 12-week baseline period with a minimum of two seizures every 4 weeks. Randomization was made to placebo, LEV 1,000 mg, or LEV 3,000 mg, with sample size based on seizure frequency reduction. The 31-item Quality of Life in Epilepsy (QOLIE-31) questionnaire was completed by 246 patients at the end of baseline and at 18-week follow-up, or earlier if withdrawn. Results: Significant differences were found among the three treatment groups for Seizure Worry (p = 0.0003), Overall Quality of Life (p = 0.04), and Cognitive Functioning domains (p = 0.01), as well as the Total Score (p = 0.009). Responders (≥50{\%} partial onset seizure reduction) had significant improvements in all areas, except Medication Effect, compared with nonresponders (all p > 0.006). Clinically noticeable improvement (≥10{\%} change from baseline to follow-up) was perceived by LEV 3,000 mg responders in all areas, except Emotional Well-Being, by LEV 1,000 mg responders in 5 of 9 areas, and by placebo responders in 2 of 9 areas. Conclusions: Addition of LEV to standard medication seems to have a positive impact on health-related quality of life, particularly among responders in this short-term study. These exploratory analyses require additional studies to evaluate long-term changes in a larger population.",
keywords = "Clinical trial, Levetiracetam, QOLIE-31, Quality of life, Seizures",
author = "Cramer, {Joyce A.} and Celestina Arrigo and {Van Hamm{\'e}e}, Genevi{\`e}ve and Gauer, {Laura J.} and James Cereghino",
year = "2000",
language = "English (US)",
volume = "41",
pages = "868--874",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Effect of levetiracetam on epilepsy-related quality of life

AU - Cramer, Joyce A.

AU - Arrigo, Celestina

AU - Van Hammée, Geneviève

AU - Gauer, Laura J.

AU - Cereghino, James

PY - 2000

Y1 - 2000

N2 - Purpose: To evaluate the short-term effect of levetiracetam (LEV; UCB L059) as add-on therapy on health-related quality of life in the treatment of refractory partial-onset seizures. Methods: Patients were enrolled in protocol UCB N132 if they had ≥ 12 partial-onset seizures with or without secondary generalization during the 12-week baseline period with a minimum of two seizures every 4 weeks. Randomization was made to placebo, LEV 1,000 mg, or LEV 3,000 mg, with sample size based on seizure frequency reduction. The 31-item Quality of Life in Epilepsy (QOLIE-31) questionnaire was completed by 246 patients at the end of baseline and at 18-week follow-up, or earlier if withdrawn. Results: Significant differences were found among the three treatment groups for Seizure Worry (p = 0.0003), Overall Quality of Life (p = 0.04), and Cognitive Functioning domains (p = 0.01), as well as the Total Score (p = 0.009). Responders (≥50% partial onset seizure reduction) had significant improvements in all areas, except Medication Effect, compared with nonresponders (all p > 0.006). Clinically noticeable improvement (≥10% change from baseline to follow-up) was perceived by LEV 3,000 mg responders in all areas, except Emotional Well-Being, by LEV 1,000 mg responders in 5 of 9 areas, and by placebo responders in 2 of 9 areas. Conclusions: Addition of LEV to standard medication seems to have a positive impact on health-related quality of life, particularly among responders in this short-term study. These exploratory analyses require additional studies to evaluate long-term changes in a larger population.

AB - Purpose: To evaluate the short-term effect of levetiracetam (LEV; UCB L059) as add-on therapy on health-related quality of life in the treatment of refractory partial-onset seizures. Methods: Patients were enrolled in protocol UCB N132 if they had ≥ 12 partial-onset seizures with or without secondary generalization during the 12-week baseline period with a minimum of two seizures every 4 weeks. Randomization was made to placebo, LEV 1,000 mg, or LEV 3,000 mg, with sample size based on seizure frequency reduction. The 31-item Quality of Life in Epilepsy (QOLIE-31) questionnaire was completed by 246 patients at the end of baseline and at 18-week follow-up, or earlier if withdrawn. Results: Significant differences were found among the three treatment groups for Seizure Worry (p = 0.0003), Overall Quality of Life (p = 0.04), and Cognitive Functioning domains (p = 0.01), as well as the Total Score (p = 0.009). Responders (≥50% partial onset seizure reduction) had significant improvements in all areas, except Medication Effect, compared with nonresponders (all p > 0.006). Clinically noticeable improvement (≥10% change from baseline to follow-up) was perceived by LEV 3,000 mg responders in all areas, except Emotional Well-Being, by LEV 1,000 mg responders in 5 of 9 areas, and by placebo responders in 2 of 9 areas. Conclusions: Addition of LEV to standard medication seems to have a positive impact on health-related quality of life, particularly among responders in this short-term study. These exploratory analyses require additional studies to evaluate long-term changes in a larger population.

KW - Clinical trial

KW - Levetiracetam

KW - QOLIE-31

KW - Quality of life

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=0033934199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033934199&partnerID=8YFLogxK

M3 - Article

C2 - 10897159

AN - SCOPUS:0033934199

VL - 41

SP - 868

EP - 874

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 7

ER -